Slotnik Capital LLC Has $1.39 Million Stock Position in Inhibrx Biosciences, Inc. $INBX

Slotnik Capital LLC cut its holdings in shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX) by 77.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,401 shares of the company’s stock after selling 142,770 shares during the period. Inhibrx Biosciences makes up 0.4% of Slotnik Capital LLC’s holdings, making the stock its 20th biggest holding. Slotnik Capital LLC’s holdings in Inhibrx Biosciences were worth $1,394,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Kennedy Capital Management LLC lifted its position in Inhibrx Biosciences by 7.5% in the 2nd quarter. Kennedy Capital Management LLC now owns 177,318 shares of the company’s stock valued at $2,530,000 after acquiring an additional 12,342 shares in the last quarter. Mark Asset Management LP acquired a new position in Inhibrx Biosciences during the 2nd quarter valued at about $243,000. Franklin Resources Inc. bought a new stake in Inhibrx Biosciences during the 2nd quarter worth approximately $316,000. Readystate Asset Management LP increased its holdings in Inhibrx Biosciences by 534.1% during the 3rd quarter. Readystate Asset Management LP now owns 170,158 shares of the company’s stock worth $5,731,000 after purchasing an additional 143,324 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Inhibrx Biosciences in the third quarter worth approximately $249,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Biosciences Stock Down 0.8%

INBX opened at $68.74 on Friday. Inhibrx Biosciences, Inc. has a fifty-two week low of $10.81 and a fifty-two week high of $94.57. The firm has a market capitalization of $999.48 million, a P/E ratio of -6.86 and a beta of 1.50. The company’s 50-day moving average is $76.38 and its 200 day moving average is $64.15. The company has a debt-to-equity ratio of 2.71, a current ratio of 4.49 and a quick ratio of 4.49.

Analyst Ratings Changes

A number of research analysts have recently weighed in on INBX shares. Weiss Ratings restated a “sell (d)” rating on shares of Inhibrx Biosciences in a report on Thursday, January 22nd. Citigroup reiterated a “market perform” rating on shares of Inhibrx Biosciences in a report on Wednesday, November 19th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Inhibrx Biosciences has a consensus rating of “Reduce”.

Inhibrx Biosciences Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.